Project

EDUC8-EDUCational Programme on Factor VIII Immunogenicity

Goal: The EDUC8 is an Innovative Training Network (ITN) funded by the European Union Horizon 2020 Programme and is composed of leading scientists dedicated to understanding the immunogenicity of therapeutic pro-coagulant factor VIII (FVIII) in patients with haemophilia A (HA), a major societal concern owing its burden on patients health and quality of life, on clinical management and on European health systems.

Updates
0 new
5
Recommendations
0 new
0
Followers
0 new
2
Reads
0 new
120

Project log

Sarah Scatigna
added an update
What's new in #HemophiliaA?
Have you already read the article recently published from Valder R. Arruda et al. ?
Their data suggest that BAFF may regulate the generation and maintenance of FVIII inhibitors and/or anti-FVIII B cells, and that anti-CD20/anti-BAFF combination therapy may be clinically useful for ITI.
Click on the following link to know more: https://www.jci.org/articles/view/142906
"B cell activating factor modulates the factor VIII immune response in hemophilia A".
#educ8 #hemophilia #HemophiliaA
 
Alejandra Reyes-Ruiz
added an update
¡Hola! I’m Alejandra Reyes Ruiz from Mexico and I'm part of the EDUC8 Network as Early Stage Researcher 1 (ESR1). I started my scientific career at Universidad Autonoma de Nuevo Leon (UANL) where I studied a bachelor degree in Biotechnology and Genomics.
A long time ago, Heraclitus rightly stated that “no man ever steps in the same river twice, for it's not the same river and he's not the same man”. We undergo continues changes, part of our cells divide and die every day to maintain homeostasis. The disruption of this balance leads to the development of pathologies as cancer. With that in mind, during my bachelor’s degree I participated in a research project focused in the mechanism of cancer cell death induced by an immunotherapy at Prof. Martínez-Torres lab.
Afterwards, I wanted to drive further into the immunology field, and I started a master’s degree in Immunology at the UANL. We must say Memento mori—“remember you must die”— to cancer cells, but also consider the better way for a cancer cell to die. In our studies, we proved that a particular immunotherapy induced a type of cell death that renders cancer cells immunogenic, which implies a therapeutic benefit in cancer patients. It is delightful how the immune system discriminates between several signals and determines the immunological consequences after cell death. I’ve come to the conclusion that immune tolerance is a fascinating phenomenon. In fact, unlike cancer, there are other pathologies in which immune tolerance is seen as a friend and not as an enemy, phenomenon that completely caught my attention.
For instance, in haemophilia A, the absence of factor VIII (FVIII) as self-antigen can lead to the development of a FVIII-specific immune response after replacement therapy in a substantial number of patients hampering further treatment. Hence, there is an urgent need to develop pioneering strategies to induce immune tolerance to FVIII in haemophilia A patients. During my PhD at Sorbonne University, I will develop novel FVIII-Fc mutant molecules to confer complete materno-foetal tolerance to FVIII. We expect that the injection of FVIII-Fc mutants to pregnant mice will lead to the transplacental delivery of FVIII, the induction of FVIII-specific Tregs in the offspring and complete long-lasting tolerance to exogenous therapeutic FVIII. This project, directed by Prof. Sebastien Lacroix-Desmazes at INSERM in Paris, France, will pave the way towards the design of novel strategies for immuno-intervention as early as during foetal life.
Starting date: 15/10/2020
 
Mariarosaria Miranda
added an update
Here is ESR2, Mariarosaria Miranda from Naples. She joined our Consortium in October and is based in Sanquin Research Institute in Amsterdam, the Netherlands. Read more about Mariarosaria below :-).
 
Sarah Scatigna
added an update
We are very excited to introduce Sarah Scatigna ESR4! She will be working at the Universitätsklinikum in Frankfurt am Main, Germany!
Read about Sarah and her project below
 
Alejandra Reyes-Ruiz
added a project goal
The EDUC8 is an Innovative Training Network (ITN) funded by the European Union Horizon 2020 Programme and is composed of leading scientists dedicated to understanding the immunogenicity of therapeutic pro-coagulant factor VIII (FVIII) in patients with haemophilia A (HA), a major societal concern owing its burden on patients health and quality of life, on clinical management and on European health systems.